ImmunoGen Competitors

ImmunoGen (NASDAQ:IMGN) and Amgen (NASDAQ:AMGN) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings.

Analyst Ratings

This is a breakdown of current recommendations and price targets for ImmunoGen and Amgen, as reported by MarketBeat.com.

ImmunoGen currently has a consensus target price of $10.10, suggesting a potential upside of 33.42%. Amgen has a consensus target price of $261.0476, suggesting a potential upside of 1.67%. Given ImmunoGen's higher probable upside, research analysts clearly believe ImmunoGen is more favorable than Amgen.

Risk and Volatility

ImmunoGen has a beta of 1.65, suggesting that its share price is 65% more volatile than the S&P 500. Comparatively, Amgen has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500.

Profitability

This table compares ImmunoGen and Amgen's net margins, return on equity and return on assets.

Institutional and Insider Ownership

73.0% of ImmunoGen shares are held by institutional investors. Comparatively, 75.2% of Amgen shares are held by institutional investors. 3.8% of ImmunoGen shares are held by company insiders. Comparatively, 0.4% of Amgen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings and Valuation

This table compares ImmunoGen and Amgen's top-line revenue, earnings per share and valuation.

Amgen has higher revenue and earnings than ImmunoGen. ImmunoGen is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Summary

Amgen beats ImmunoGen on 10 of the 14 factors compared between the two stocks.

ImmunoGen (NASDAQ:IMGN) and Gilead Sciences (NASDAQ:GILD) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings.

Analyst Ratings

This is a breakdown of current recommendations and price targets for ImmunoGen and Gilead Sciences, as reported by MarketBeat.com.

ImmunoGen currently has a consensus target price of $10.10, suggesting a potential upside of 33.42%. Gilead Sciences has a consensus target price of $97.92, suggesting a potential upside of 47.58%. Given Gilead Sciences' higher probable upside, analysts clearly believe Gilead Sciences is more favorable than ImmunoGen.

Risk and Volatility

ImmunoGen has a beta of 1.65, suggesting that its share price is 65% more volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500.

Profitability

This table compares ImmunoGen and Gilead Sciences' net margins, return on equity and return on assets.

Institutional and Insider Ownership

73.0% of ImmunoGen shares are held by institutional investors. Comparatively, 76.4% of Gilead Sciences shares are held by institutional investors. 3.8% of ImmunoGen shares are held by company insiders. Comparatively, 0.1% of Gilead Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings and Valuation

This table compares ImmunoGen and Gilead Sciences' top-line revenue, earnings per share and valuation.

Gilead Sciences has higher revenue and earnings than ImmunoGen. ImmunoGen is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Summary

Gilead Sciences beats ImmunoGen on 10 of the 14 factors compared between the two stocks.

ImmunoGen (NASDAQ:IMGN) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings.

Analyst Ratings

This is a breakdown of current recommendations and price targets for ImmunoGen and Vertex Pharmaceuticals, as reported by MarketBeat.com.

ImmunoGen currently has a consensus target price of $10.10, suggesting a potential upside of 33.42%. Vertex Pharmaceuticals has a consensus target price of $293.1250, suggesting a potential upside of 32.98%. Given ImmunoGen's higher probable upside, research analysts clearly believe ImmunoGen is more favorable than Vertex Pharmaceuticals.

Risk and Volatility

ImmunoGen has a beta of 1.65, suggesting that its share price is 65% more volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500.

Profitability

This table compares ImmunoGen and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Institutional and Insider Ownership

73.0% of ImmunoGen shares are held by institutional investors. Comparatively, 92.2% of Vertex Pharmaceuticals shares are held by institutional investors. 3.8% of ImmunoGen shares are held by company insiders. Comparatively, 0.7% of Vertex Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings and Valuation

This table compares ImmunoGen and Vertex Pharmaceuticals' top-line revenue, earnings per share and valuation.

Vertex Pharmaceuticals has higher revenue and earnings than ImmunoGen. ImmunoGen is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Vertex Pharmaceuticals beats ImmunoGen on 11 of the 15 factors compared between the two stocks.

ImmunoGen (NASDAQ:IMGN) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings.

Analyst Ratings

This is a breakdown of current recommendations and price targets for ImmunoGen and Regeneron Pharmaceuticals, as reported by MarketBeat.com.

ImmunoGen currently has a consensus target price of $10.10, suggesting a potential upside of 33.42%. Regeneron Pharmaceuticals has a consensus target price of $646.2609, suggesting a potential upside of 28.80%. Given ImmunoGen's higher probable upside, research analysts clearly believe ImmunoGen is more favorable than Regeneron Pharmaceuticals.

Risk and Volatility

ImmunoGen has a beta of 1.65, suggesting that its share price is 65% more volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.3, suggesting that its share price is 70% less volatile than the S&P 500.

Profitability

This table compares ImmunoGen and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.

Institutional and Insider Ownership

73.0% of ImmunoGen shares are held by institutional investors. Comparatively, 85.0% of Regeneron Pharmaceuticals shares are held by institutional investors. 3.8% of ImmunoGen shares are held by company insiders. Comparatively, 11.8% of Regeneron Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings and Valuation

This table compares ImmunoGen and Regeneron Pharmaceuticals' top-line revenue, earnings per share and valuation.

Regeneron Pharmaceuticals has higher revenue and earnings than ImmunoGen. ImmunoGen is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Regeneron Pharmaceuticals beats ImmunoGen on 12 of the 15 factors compared between the two stocks.

ImmunoGen (NASDAQ:IMGN) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings.

Earnings and Valuation

This table compares ImmunoGen and Biogen's top-line revenue, earnings per share and valuation.

Biogen has higher revenue and earnings than ImmunoGen. ImmunoGen is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

ImmunoGen has a beta of 1.65, suggesting that its share price is 65% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations and price targets for ImmunoGen and Biogen, as reported by MarketBeat.com.

ImmunoGen currently has a consensus target price of $10.10, suggesting a potential upside of 33.42%. Biogen has a consensus target price of $303.5862, suggesting a potential upside of 12.12%. Given ImmunoGen's stronger consensus rating and higher probable upside, research analysts clearly believe ImmunoGen is more favorable than Biogen.

Profitability

This table compares ImmunoGen and Biogen's net margins, return on equity and return on assets.

Institutional and Insider Ownership

73.0% of ImmunoGen shares are held by institutional investors. Comparatively, 83.5% of Biogen shares are held by institutional investors. 3.8% of ImmunoGen shares are held by company insiders. Comparatively, 0.5% of Biogen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Biogen beats ImmunoGen on 9 of the 14 factors compared between the two stocks.

ImmunoGen (NASDAQ:IMGN) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings.

Earnings & Valuation

This table compares ImmunoGen and Alexion Pharmaceuticals' top-line revenue, earnings per share and valuation.

Alexion Pharmaceuticals has higher revenue and earnings than ImmunoGen. ImmunoGen is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

ImmunoGen has a beta of 1.65, suggesting that its stock price is 65% more volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and target prices for ImmunoGen and Alexion Pharmaceuticals, as reported by MarketBeat.com.

ImmunoGen currently has a consensus target price of $10.10, suggesting a potential upside of 33.42%. Alexion Pharmaceuticals has a consensus target price of $153.8636, suggesting a potential downside of 6.17%. Given ImmunoGen's stronger consensus rating and higher probable upside, analysts clearly believe ImmunoGen is more favorable than Alexion Pharmaceuticals.

Profitability

This table compares ImmunoGen and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Institutional & Insider Ownership

73.0% of ImmunoGen shares are held by institutional investors. Comparatively, 87.3% of Alexion Pharmaceuticals shares are held by institutional investors. 3.8% of ImmunoGen shares are held by company insiders. Comparatively, 4.0% of Alexion Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Alexion Pharmaceuticals beats ImmunoGen on 11 of the 15 factors compared between the two stocks.